Response of refractory anemia to low-dose cytosine arabinoside
Gallo, J.H.; Rozenberg, M.C.
Australian and New Zealand Journal of Medicine 16(2): 231-233
1986
ISSN/ISBN: 0004-8291 PMID: 3463278 Document Number: 270809
Two elderly patients with transfusion-dependent refractory anemia due to myelodysplastic syndromes were treated with a course of low-dose subcutaneous cytosine arabinoside in an attempt to reduce their transfusion requirements. Following treatment, they required no transfusions for over six months. The treatment was well tolerated, but was associated with initial myelosuppression.
Document emailed within 1 workday
Related Documents
Klener, P.; Háber, J. 1985: Treatment of refractory leukemia with high-dose cytosine arabinoside Neoplasma 32(1): 113-117Ohshima, A.; Yoshida, K.; Sato, T.; Miyazaki, S.; Yanagisawa, M.; Nakayama, Y.; Takahashi, T.; Mamiya, S.; Fukusima, Y.; Miura, A.B. 1987: Intermediate- and high-dose cytosine arabinoside therapy in acute refractory leukemia Gan to Kagaku Ryoho. Cancer and ChemoTherapy 14(1): 192-195
Wakita, A.; Murase, T.; Uchida, T.; Fujiwara, Y.; Tanaka, M.; Ohkita, T. 1992: Mitoxantrone and conventional-dose cytosine arabinoside for relapsed and refractory acute leukemia Gan to Kagaku Ryoho. Cancer and ChemoTherapy 19(5): 653-657
Takemoto, Y.; Sampi, K.; Kuraishi, Y.; Okabe, K.; Tamura, K.; Mizoguchi, H.; Saito, H.; Masaoka, T.; Ogawa, M. 1999: A prospective randomized trial of KRN8602 and cytosine arabinoside vs. daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. the KRN8602 Leukemia Study Group International Journal of Hematology 70(1): 20-25
Lin, S.F.; Liu, H.W.; Chen, T.P. 1990: Chemotherapy for acute non-lymphocytic leukemia with low-dose cytosine arabinoside (Ara-C) Nihon Ketsueki Gakkai Zasshi: Journal of Japan Haematological Society 53(1): 45-50
Pedersen, G.; Stentoft, J.; Pedersen, J.O.; Jensen, M.K. 1994: Treatment of acute myeloid leukemia in the elderly with low-dose cytosine arabinoside Ugeskrift for Laeger 156(43): 6380-6384
Herzig, R.H.; Herzig, G.P.; Wolff, S.N.; Hines, J.D.; Fay, J.W.; Phillips, G.L. 1987: Central nervous system effects of high-dose cytosine arabinoside Seminars in Oncology 14(2 Suppl 1: 21-24
Nemet, D.; Labar, B.; Bogdanić, V.; Hauptman, E.; Jaksić, B.; Minigo, H.; Sertić, D.; Mrsić, M.; Pavletić, Z.; Kovacević, J. 1989: High dose cytosine arabinoside in the treatment of adult acute myelogenous leukaemia Bone Marrow Transplantation 4(Suppl 3): 42-44
Wysocki, M.; Nowaczyk-Michalak, A.; Pilecki, O.; Trybuś, L.; Balcar-Boroń, A. 1992: Jaundice following high--dose arabinoside cytosine in a child with acute myelogenous leukemia Acta Haematologica Polonica 23(3): 197-199
Keating, M.J.; Estey, E.; Plunkett, W.; Iacoboni, S.; Walters, R.; Kantarjian, H.; Andersson, B.; Beran, M.; McCredie, K.B.; Freireich, E.J. 1985: Evolution of clinical studies with high-dose cytosine arabinoside at the M.D. Anderson Hospital Seminars in Oncology 12(2 Suppl. 3): 98-104
Kobayashi, S.; Sakai, H.; Tomiazwa, T.; Koiso, H.; Kim, K.; Ueki, K.; Tamura, J.; Yano, S.; Naruse, T.; Karasawa, M. 1999: Successful low-dose cytosine arabinoside treatment in a patient with acute leukemia from idiopathic myelofibrosis Journal of Medicine 30(1-2): 101-109
Huang, M.E.; Ye, Y.C.; Zhao, L. 1987: Treatment of acute promyelocytic leukemia by retinoic acid with or without low dose cytosine arabinoside: report of 4 cases Zhonghua Nei Ke Za Zhi 26(6): 330
Herzig, R.H.; Coccia, P.F.; Lazarus, H.M.; Strandjord, S.E.; Graham-Pole, J.; Cheung, N.K.; Gordon, E.M.; Gross, S.; Spitzer, T.R.; Warkentin, P.I. 1985: Bone marrow transplantation for acute leukemia and lymphoma with high-dose cytosine arabinoside and total body irradiation Seminars in Oncology 12(2 Suppl 3: 184-186
Johnson, N.T.; Crawford, S.W.; Sargur, M. 1987: Acute acquired demyelinating polyneuropathy with respiratory failure following high-dose systemic cytosine arabinoside and marrow transplantation Bone Marrow Transplantation 2(2): 203-207
Brusamolino, E.; Passamonti, F.; Pagnucco, G.; Castagnola, C.; Lazzarino, M.; Bernasconi, C. 1998: Efficacy of a combination of idarubicin, etoposide and intermediate-dose cytosine arabinoside as salvage therapy in relapsing or resistant unfavorable lymphoma Haematologica 83(4): 323-328
Osugi, Y.; Keisei, K.H.; Murayama, N.; Inoue, M.; Ishihara, S.; Hara, J.; Yagi, K.; Tawa, A.; Okada, S.; Izumi, Y. 1990: Effects of recombinant human granulocyte colony stimulating factor following high-dose cytosine arabinoside therapy in children with malignancy Gan to Kagaku Ryoho. Cancer and ChemoTherapy 17(7): 1379-1382
Ghaddar, H.M.; Plunkett, W.; Kantarjian, H.M.; Pierce, S.; Freireich, E.J.; Keating, M.J.; Estey, E.H. 1994: Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside Leukemia 8(8): 1269-1274
Sanz, M.A.; Martínez, J.; Borrego, D.; Martín-Aragonés, G.; Lorenzo, I.; Sanz, G.; Sayas, M.J.; Jarque, I.; Pastor, E.; Rafecas, J. 1987: High-dose cytosine arabinoside and mitoxantrone in high-risk acute nonlymphoblastic leukemia Seminars in Oncology 14(2 Suppl 1): 18-20
Guilhot, F. 1993: Interferon alfa and low-dose cytosine-arabinoside for the treatment of patients with chronic myelogenous leukemia in chronic phase. French CML Study Group Seminars in Hematology 30(3 Suppl 3: 24-25
Nagatoshi, Y.; Okamura, J.; Ikuno, Y.; Akamatsu, M.; Tasaka, H. 1997: Therapeutic trial of intensified conditioning regimen with high-dose cytosine arabinoside, cyclophosphamide and either total body irradiation or busulfan followed by allogeneic bone marrow transplantation for myelodysplastic syndrome in children International Journal of Hematology 65(3): 269-275